New Delhi based Mankind Pharma has joined the crowded anti diabetic drug war by launching its own version of the gliptin, a new class of anti-diabetic drug that has triggered price war among drug makers. Mankind on Monday said it has launched Dynaglipt at Rs 600 for a 30 day course, pitting itself against companies like Glenmark and Zydus who have launched their own variant of Teneligliptin this year.
India's anti-diabetic market is one of the fastest growing therapy segments, with a growth exceeding 25% at Rs 7638 crore, according to the October data released by All India Organization of Chemists and Druggists Association (AIOCD).
Gliptins, also termed DPP-4 inhibitors, have become a runaway success among all anti-diabetes drugs. These drugs help induce appropriate insulin levels in the blood. With over 60 million patients, India has earned the dubious reputation of being the diabetes capital of the world.
Global drug firms have dominated the market for gliptins led by MSD, Novartis, AstraZeneca and Boehringer Ingelheim which have partnered with their Indian counterparts like Sun and Lupin to market their products.
Read More:
- Biotech Lab Gets Research Grant to evaluate Life on Mars !
- Google Glass Helps To Unclog Artery
- Functional Artificial Pancreas Developed
- New 'Biogel' That Kills Cancer Cells